Background: Health-related cannabis has been out there in the State of Minnesota given that July 2015 via the Minnesota Health-related Cannabis Program (MMCP). Objectives: Our study aimed to delineate oncology providers’ views on healthcare cannabis, recognize barriers to patient enrollment, and assess clinicians’ interest in a clinical trial of healthcare cannabis in individuals with stage IV cancer. Strategies: From June to August 2017, we distributed a 14-query survey to Minnesota oncology physicians, sophisticated practice nurses, and doctor assistants who care for adults and young children with cancer. Descriptive analyses for every query had been supplied for all survey respondents. Benefits: Of the 529 eligible survey participants, 153 (29%) responded to our survey 68 respondents had been registered with the MMCP. Most identified themselves as a healthcare oncologist or healthcare oncology nurse practitioner/doctor assistant (n=125, 82%), and most practiced in a neighborhood setting (n=102, 67%). General, 65% of respondents supported the use of healthcare cannabis. Perceived price and inadequate study had been the highest barriers to MMCP patient enrollment. The lowest barriers incorporated lack of overall health group assistance for permitting certification of individuals and danger of social stigma. Of all respondents, 36% lacked self-confidence in discussing the dangers and rewards of healthcare cannabis, and 85% wanted far more education. Conclusions: Although assistance for cannabis use in the cancer setting is developing, important barriers stay. This study illustrates a clear have to have to give clinicians each information and education to guide their discussions about the rewards, dangers, and price considerations of using healthcare cannabis for cancer-associated symptoms.
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 30426072 PMCID: PMC6225592 DOI: 10.1089/can.2018.0029
Zylla D1,two, Steele G1,two, Eklund J1,two, Mettner Jtwo, Arneson Tthree.